12:00 AM
Apr 17, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

GBC-590: Began Phase II trial

SafeScience Inc. (SAFS), Boston, Mass.
Product: GBC-590
Business: Cancer
Therapeutic category: Cell proliferation
Target: Cell surface...

Read the full 56 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >